Page 8 of 21 – SEC Filing CUSIP No. G0750W104 13D Page 8 of 21 Pages
1 NAMES OF REPORTING PERSONS
Viking Long Fund Master Ltd.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)
o
(b)
x
3 SEC USE ONLY 4 SOURCE OF FUNDS(see instructions)
OO (See Item 3)
5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o 6 CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF SHARES
BENEFICIALLY OWNED BY
EACH REPORTING
PERSON WITH
7 SOLE VOTING POWER
0
8 SHARED VOTING POWER
0
9 SOLE DISPOSITIVE POWER
0
10 SHARED DISPOSITIVE POWER
75,000,000
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON
75,000,000
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) o 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
75.6%*
14 TYPE OF REPORTING PERSON
CO
* The calculation assumes that there are a total of 99,150,000 Common Shares outstanding as of June 3, 2016, as reported by the
Issuer on its Annual Report on Form 10-K for the fiscal year ended March 31, 2016, filed with the SEC on June 6, 2016.
| CUSIP No. G0750W104 | 13D | Page 8 of 21 Pages |
| 1 | NAMES OF REPORTING PERSONS Viking Long Fund Master Ltd. | |||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) (b) | |||||
| 3 | SEC USE ONLY | |||||
| 4 | SOURCE OF FUNDS(see instructions) OO (See Item 3) | |||||
| 5 | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) | o | ||||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY PERSON WITH | 7 | SOLE VOTING POWER 0 | ||||
| 8 | SHARED VOTING POWER 0 | |||||
| 9 | SOLE DISPOSITIVE POWER 0 | |||||
| 10 | SHARED DISPOSITIVE POWER 75,000,000 | |||||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING 75,000,000 | |||||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) | o | ||||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 75.6%* | |||||
| 14 | TYPE OF REPORTING PERSON CO | |||||
| * | The calculation assumes that there are a total of 99,150,000 Common Shares outstanding as of June 3, 2016, as reported by the Issuer on its Annual Report on Form 10-K for the fiscal year ended March 31, 2016, filed with the SEC on June 6, 2016. |
Follow Sio Gene Therapies Inc. (NASDAQ:SIOX)
Follow Sio Gene Therapies Inc. (NASDAQ:SIOX)
Receive real-time insider trading and news alerts





